Weight loss in neurodegenerative disorders

被引:96
作者
Aziz, N. Ahmad [1 ]
van der Marck, Marjolein A. [3 ]
Pijl, Hanno [2 ]
Rikkert, Marcel G. M. Olde [4 ]
Bloem, Bastiaan R. [3 ]
Roos, Raymund A. C. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, NL-2300 RC Leiden, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6525 ED Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Dept Geriatr Med, NL-6525 ED Nijmegen, Netherlands
关键词
weight loss; neurodegenerative disorders; Alzheimer's disease; Parkinson's disease; Huntington's disease;
D O I
10.1007/s00415-009-0062-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Unintended weight loss frequently complicates the course of many neurodegenerative disorders and can contribute substantially to both morbidity and mortality. This will be illustrated here by reviewing the characteristics of unintended weight loss in the three major neuro degenerative disorders: Alzheimer's disease, Parkinson's disease and Huntington's disease. A common denominator of weight loss in these neurodegenerative disorders is its typically complex pathophysiology. Timely recognition of the underlying pathophysiological process is of crucial importance, since a tailored treatment of weight loss can considerably improve the quality of life. This treatment is, primarily, comprised of a number of methods of increasing energy intake. Moreover, there are indications for defects in the systemic energy homeostasis and gastrointestinal function, which may also serve as therapeutic targets. However, the clinical merits of such interventions have yet to be demonstrated.
引用
收藏
页码:1872 / 1880
页数:9
相关论文
共 98 条
[1]   Midlife adiposity and the future risk of Parkinson's disease [J].
Abbott, RD ;
Ross, GW ;
White, LR ;
Nelson, JS ;
Masaki, KH ;
Tanner, CM ;
Curb, JD ;
Blanchette, PL ;
Popper, JS ;
Petrovitch, H .
NEUROLOGY, 2002, 59 (07) :1051-1057
[2]  
[Anonymous], 2006, NUTR SUPP AD OR NUTR
[3]  
[Anonymous], - Malnutrition Universal Screening Tool (MUST)
[4]  
[Anonymous], 2002, Huntington's disease
[5]   Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease [J].
Arabia, G ;
Zappia, M ;
Bosco, D ;
Crescibene, L ;
Bagalà, A ;
Bastone, L ;
Caracciolo, M ;
Scornaienghi, M ;
Quattrone, A .
NEUROLOGICAL SCIENCES, 2002, 23 (Suppl 2) :S53-S54
[6]   Hypocretin and melanin-concentrating hormone in patients with Huntington disease [J].
Aziz, Ahmad ;
Fronczek, Rolf ;
Maat-Schieman, Marion ;
Unmehopa, Unga ;
Roelandse, Freek ;
Overeem, Sebastiaan ;
van Duinen, Sjoerd ;
Lammers, Gert-Jan ;
Swaab, Dick ;
Roos, Raymund .
BRAIN PATHOLOGY, 2008, 18 (04) :474-483
[7]  
Aziz NA, 2007, REV NEUROSCIENCE, V18, P223
[8]   Body weight in patients with Parkinson's disease [J].
Bachmann, Cornelius G. ;
Trenkwalder, Claudia .
MOVEMENT DISORDERS, 2006, 21 (11) :1824-1830
[9]   WEIGHT CHANGE AND BODY-COMPOSITION IN PATIENTS WITH PARKINSONS-DISEASE [J].
BEYER, PL ;
PALARINO, MY ;
MICHALEK, D ;
BUSENBARK, K ;
KOLLER, WC .
JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 1995, 95 (09) :979-983
[10]   Change in body mass index and risk of incident Alzheimer disease [J].
Buchman, AS ;
Wilson, RS ;
Bienias, JL ;
Shah, RC ;
Evans, DA ;
Bennett, DA .
NEUROLOGY, 2005, 65 (06) :892-897